Vanguard National Trust’s NovoCure NVCR Stock Holding History

Vanguard National Trust’s Portfolio NVCR Stock Details NVCR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-11	Closed	-$120	–	812
2026 Q1	$120	Buy	+11	New	+$137	﹤0.01%	741

Other funds holding NVCR

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

SCM

Soleus Capital Management Greenwich, Connecticut $2.9B AUM 169.69% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Wells Fargo San Francisco, California $617B AUM 30.33% 1-Year Est. Return

QCM

Quantinno Capital Management New York $83.3B AUM 37.97% 1-Year Est. Return

Vanguard National Trust's NVCR Position: Q2 2026 in Review

Vanguard National Trust sold out of NovoCure (NVCR) in Q2 2026, closing a stake of 11 shares — an estimated $120 sold.

Vanguard National Trust first reported a position in NVCR in Q1 2026 and held it in 1 quarter. The position peaked at $120 in Q1 2026. 215 funds tracked by Wall St. Rank hold NVCR as of Q2 2026.

Vanguard National Trust reported no remaining NovoCure position as of Q2 2026 after selling out during the quarter.
Vanguard National Trust sold 11 NovoCure shares in Q2 2026, an estimated $120.
Vanguard National Trust first reported a position in NovoCure in Q1 2026 and held it in 1 quarter.
Vanguard National Trust's NovoCure position peaked at $120 in Q1 2026.
215 funds tracked by Wall St. Rank held NovoCure as of Q2 2026.

Based on Vanguard National Trust's 13F filing for Q2 2026, filed 13 Aug 2026.